📊 GTHP Key Takeaways
Is Guided Therapeutics Inc. (GTHP) a Good Investment?
GTHP exhibits critical financial distress with negative stockholders equity (-$6.0M), severe insolvency (liabilities 5.6x assets), and catastrophic liquidity (current ratio 0.09x with only $63K cash). The company burns $1.1M annually in operating cash flow while generating just $767K in revenue, creating an unsustainable burn profile that exhausts remaining cash within weeks.
Despite a sharp rebound in revenue and strong gross margins, Guided Therapeutics remains deeply unprofitable with severe liquidity and solvency stress. Negative equity, minimal cash, and large current obligations alongside persistent operating losses and negative operating cash flow indicate reliance on external financing. Until the company achieves sustained cash generation and materially repairs its balance sheet, fundamentals remain unfavorable.
Why Buy Guided Therapeutics Inc. Stock? GTHP Key Strengths
- Gross margin of 74.4% indicates viable core product economics at scale
- Massive 10,857% YoY revenue growth suggests emerging market traction despite small absolute base
- Zero long-term debt simplifies balance sheet restructuring options
- High gross margin (~74%) suggesting attractive unit economics
- Large YoY revenue growth off a low base
- Asset-light model with minimal capex and no long-term debt
GTHP Stock Risks: Guided Therapeutics Inc. Investment Risks
- Negative stockholders equity of -$6.0M indicates balance sheet insolvency and existential bankruptcy risk
- Cash position of $63K with -$1.1M annual operating cash burn creates immediate liquidity crisis (weeks of runway)
- Operating margin of -309.3% and net margin of -416.7% demonstrate business model is not yet viable at current scale
- Current ratio of 0.09x and quick ratio of 0.02x show inability to service current liabilities
- Revenue growth from near-zero base ($7K prior year) lacks credibility without sustained scale
- Going-concern risk given current ratio ~0.09x, minimal cash, and negative equity
- Persistent operating losses and negative interest coverage
- Dependence on external financing with potential dilution and unfavorable terms
Key Metrics to Watch
- Cash runway and financing needs - critical for survival
- Operating cash flow trend - must turn positive or company faces imminent insolvency
- Revenue sustainability above $1M+ quarterly threshold - needed to approach breakeven operations
- Debt covenant compliance and creditor negotiations - key to avoiding forced restructuring
- Operating cash flow (OCF)
- Cash and equivalents (quarter-end)
Guided Therapeutics Inc. (GTHP) Financial Metrics & Key Ratios
💡 AI Analyst Insight
The current ratio below 1.0x warrants monitoring of short-term liquidity.
GTHP Profit Margin, ROE & Profitability Analysis
GTHP vs Healthcare Sector: How Guided Therapeutics Inc. Compares
How Guided Therapeutics Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Guided Therapeutics Inc. Stock Overvalued? GTHP Valuation Analysis 2026
Based on fundamental analysis, Guided Therapeutics Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Guided Therapeutics Inc. Balance Sheet: GTHP Debt, Cash & Liquidity
GTHP Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Guided Therapeutics Inc.'s revenue has grown significantly by 652% over the 5-year period, indicating strong business expansion. The most recent EPS of $-0.05 indicates the company is currently unprofitable.
GTHP Revenue Growth, EPS Growth & YoY Performance
GTHP Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | N/A | -$654.0K | $-0.01 |
| Q2 2025 | N/A | -$709.0K | $-0.01 |
| Q1 2025 | N/A | -$402 | $-0.01 |
| Q3 2024 | N/A | -$654.0K | $-0.01 |
| Q2 2024 | N/A | -$709.0K | $-0.01 |
| Q1 2024 | $6.0K | -$402.0K | $-0.01 |
| Q3 2023 | N/A | -$677.0K | $-0.01 |
| Q2 2023 | $5.0K | -$926.0K | $-0.03 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Guided Therapeutics Inc. Dividends, Buybacks & Capital Allocation
GTHP SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Guided Therapeutics Inc. (CIK: 0000924515)
📋 Recent SEC Filings
❓ Frequently Asked Questions about GTHP
What is the AI rating for GTHP?
Guided Therapeutics Inc. (GTHP) has a Combined AI Rating of STRONG SELL from Claude (STRONG SELL) and ChatGPT (STRONG SELL) with 92% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are GTHP's key strengths?
Claude: Gross margin of 74.4% indicates viable core product economics at scale. Massive 10,857% YoY revenue growth suggests emerging market traction despite small absolute base. ChatGPT: High gross margin (~74%) suggesting attractive unit economics. Large YoY revenue growth off a low base.
What are the risks of investing in GTHP?
Claude: Negative stockholders equity of -$6.0M indicates balance sheet insolvency and existential bankruptcy risk. Cash position of $63K with -$1.1M annual operating cash burn creates immediate liquidity crisis (weeks of runway). ChatGPT: Going-concern risk given current ratio ~0.09x, minimal cash, and negative equity. Persistent operating losses and negative interest coverage.
What is GTHP's revenue and growth?
Guided Therapeutics Inc. reported revenue of $767.0K.
Does GTHP pay dividends?
Guided Therapeutics Inc. does not currently pay dividends.
Where can I find GTHP SEC filings?
Official SEC filings for Guided Therapeutics Inc. (CIK: 0000924515) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is GTHP's EPS?
Guided Therapeutics Inc. has a diluted EPS of $-0.04.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is GTHP a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Guided Therapeutics Inc. has a STRONG SELL rating with 92% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is GTHP stock overvalued or undervalued?
Valuation metrics for GTHP: ROE of N/A (sector avg: 15%), net margin of -416.7% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy GTHP stock in 2026?
Our dual AI analysis gives Guided Therapeutics Inc. a combined STRONG SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is GTHP's free cash flow?
Guided Therapeutics Inc.'s operating cash flow is $-1.1M, with capital expenditures of $2.0K. FCF margin is -139.5%.
How does GTHP compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -416.7% (avg: 12%), ROE N/A (avg: 15%), current ratio 0.09 (avg: 2).